Nanobiotix S.A. ADR NBTX 深 沪
已收盘 11-07 16:00:00 美东时间
19.87
+0.200
+1.02%
华盛通- 最 高20.105
- 今 开19.80
- 成交量 7.85万股
- 最 低 19.03
- 昨 收 19.67
- 总市值 9.58亿
- 52周最高 30.35
- 市盈率 静 --
- 换手率 0.16%
- 52周最低 2.76
- 委 比 98.02%
- 总股本 4821.47万
- 历史最高 30.35
- 量 比 0.84
- 振 幅 5.47%
- 历史最低 1.75
- 每 手 1
- 风险率 6.08%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Alphatec Holdings (NASDAQ:ATEC) shares rose 21.7% to $19.88 during Fri...
10-31 20:10
Nanobiotix And HealthCare Royalty Ink 71M Non-Dilutive Financing Agreement To Support JNJ-1900 (NBTXR3) Development And Long-Term Growth
$71 million in funding would extend Nanobiotix cash visibility into early 2028Transaction enables Nanobiotix development beyond key milestones in head and neck cancer and lung cancerFinancing establishes financial
10-31 15:18
Wayfair, Qorvo, Celestica, United Parcel Service, Regeneron Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on ...
10-28 22:14
NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control
Nanobiotix announced the completion of transferring sponsorship and operational control of the NANORAY-312 clinical trial for JNJ-1900 (NBTXR3) to Johnson & Johnson. Interim data analysis is expected in 1H2027 after recruitment and requisite events. Nanobiotix will continue to provide updates on its sponsored studies and collaborations. JNJ-1900, a novel oncology product, is activated by radiotherapy and has shown potential in treating solid tumo...
10-24 06:00
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining aroun...
10-20 20:10
Dell, Select Medical, Century Aluminum And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 100 points on ...
10-08 22:39
Nanobiotix SA ADR Reports Revenue Surge Amid Strategic Advances
Nanobiotix Sa ADR ( ($NBTX) ) has released its Q2 earnings. Here is a breakdown...
10-04 11:50
Nanobiotix S.A. GAAP EPS of -€0.11, revenue of €26.6M
Nanobiotix S.A. press release (OTC:NNBXF): 1H GAAP EPS of -€0.11. Revenue of €26.6M. More on Nanobiotix Nanobiotix: Today's Data Readout For Radiation Therapy Enhances Bull Case Nanobiotix S.A. (NBTX)...
10-01 22:07
NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
NANOBIOTIX announced initial Phase 1 data for JNJ-1900 (NBTXR3) in locally advanced esophageal adenocarcinoma, showing an 85% disease control rate (DCR) and 69% objective response rate (ORR) in 13 patients. The treatment was well-tolerated with no grade 3+ adverse events related to the injection procedure. The study is ongoing with 17 additional patients being recruited. JNJ-1900, a radioenhancer, has shown promise in enhancing local tumor contro...
10-01 20:15
Nanobiotix Releases Half-Year Financial Report Highlighting JNJ-1900 Developments
Nanobiotix ( ($NBTX) ) just unveiled an announcement. On September 30, 2025, Na...
10-01 04:54
